Venetoclax in Patients With MDS or AML in Relapse After AHSCT

Sponsor
Groupe Francophone des Myelodysplasies (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05226455
Collaborator
AbbVie (Industry)
48
14
1
42
3.4
0.1

Study Details

Study Description

Brief Summary

Study to assess venetoclax + azacitidine and donor lymphocyte infusion (DLI) in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) with blasts < 30% in relapse after allohematopoietic stem cell transplantation (AHSCT).

Condition or Disease Intervention/Treatment Phase
  • Drug: venetoclax + azacitidine +/- donor lymphocyte infusion
Phase 1/Phase 2

Detailed Description

A phase I-II study to assess venetoclax + azacitidine and donor lymphocyte infusion (DLI) in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) with blasts < 30% in relapse after allohematopoietic stem cell transplantation (AHSCT).

Study Design

Study Type:
Interventional
Anticipated Enrollment :
48 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Phase I-II Study to Assess Venetoclax + Azacitidine and Donor Lymphocyte Infusion in Patients With MDS or AML (Blasts < 30%) in Relapse After Allohematopoietic Stem Cell Transplantation
Anticipated Study Start Date :
Sep 1, 2022
Anticipated Primary Completion Date :
Sep 1, 2025
Anticipated Study Completion Date :
Mar 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: venetoclax + azacitidine +/- donor lymphocyte infusion

Venetoclax + azacitidine +/- donor lymphocyte infusion (maximum 12 cycles). Venetoclax: on D1 to D14 of 28 days cycle ; Phase I: 4 dose levels: 50, 100, 200, 400 mg/d, starting dose at 100 mg ; Phase II: dose defined in the phase I. Azacitidine 75 mg/m²/d or 50 mg/m²/d (if allohematopoietic stem cell transplantation relapse < 4 months) x 5 days (on D1 to D5 of 28 days cycle).

Drug: venetoclax + azacitidine +/- donor lymphocyte infusion
Venetoclax will be given once daily orally on days 1 to 14 for all cycles. Venetoclax + azacitidine +/- donor lymphocyte infusion (12 cycles maximum)
Other Names:
  • venclyxto
  • vidaza
  • Outcome Measures

    Primary Outcome Measures

    1. Phase I: Dose-finding study [At the end of cycle 1 of venetoclax + azacitidine (each cycle is 28 days)]

      Evaluation of Dose-limiting toxicity (DLT) to determine the optimal dose level in terms of both toxicity and safety for venetoclax + azacitidine

    2. Phase II: Overall improvement rate of venetoclax + azacitidine +/- DLI [After 8 cycles of venetoclax + azacitidine (each cycle is 28 days)]

      Response assessment performed according to modified IWG (International Working Group) 2006 criteria for myelodysplastic syndrome and to European Leukemia Net criteria for acute myeloid leukemia

    Secondary Outcome Measures

    1. Toxicity assessment [At 42 months (at end of study)]

      Adverse events analyzed by frequency, NCI CTCAE 5.0 grade, and causality

    2. Graft-versus-Host-Disease (GVHD) rate [At 42 months (at end of study)]

      Acute and chronic graft-versus-host-disease (GVHD) rate assessment (graft-versus-host events analyzed by frequency and grade)

    3. Duration of response [At 42 months (at end of study)]

      Duration of response defined as time from the date of the first observed response (complete or partial) to the date of first subsequent documented disease progression or relapse or death

    4. Overall survival [At 42 months (at end of study)]

      Overall Survival defined as time from the date of the first dose of venetoclax to the date of death or end of study

    5. Progression-free survival [At 42 months (at end of study)]

      Progression-free Survival for patients with at least a partial response defined as time from the date of the first dose of venetoclax to the date of the first documented disease progression or relapse or death

    6. Event-free survival [At 42 months (at end of study)]

      Event-free Survival defined as time from the date of the first dose of venetoclax to the date of earliest disease progression or death

    Other Outcome Measures

    1. Correlation between patient overall mutational status before and after treatment [At 42 months (at end of study)]

      Mutational analysis performed by NGS (next-generation sequencing) at screening and then at each protocol evaluation (post 4, 6 and 8 cycles of venetoclax + azacitidine and at end of study)

    2. Prognostic impact of Minimal Residual Disease (MRD) on outcome [At 42 months (at end of study)]

      Minimal Residual Disease (MRD) assessment by flow cytometry and allelic variant frequency (VAF) of baseline mutations

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Documented relapse of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) with marrow blasts < 30% (with white blood cells (WBC) < 15000/mm3), after allohematopoietic stem cell transplantation.
    Relapse of MDS or AML is defined as :
    • Return to pretreatment bone marrow blast percentage

    • Decrement of at least 50% from maximum remission

    1. Age ≥ 18 years.

    2. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.

    3. Patient must have adequate organ function:

    • Serum creatinine < 2 mg/dL or calculated creatinine clearance ≥ 30 mL/min for patients with creatinine levels > 1.5 times Upper Limit of Normal

    • Serum total bilirubin ≤ 2.5 times Upper Limit of Normal or direct bilirubin ≤ Upper Limit of Normal for patients with total bilirubin levels ≥ 2 mg/d

    • Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 2.5 times Upper Limit of Normal

    • Alkaline phosphatase ≤ 5 times Upper Limit of Normal (if > 2.5 times Upper Limit of Normal, then liver fraction should be ≤ 2.5 times Upper Limit of Normal).

    1. Patient not refractory to platelet transfusions.

    2. Female subject of childbearing potential must practice at least one protocol specified method of birth control, starting on Study Day 1 through at least 30 days after the last dose of venetoclax or 3 months after the last dose of azacitidine.

    Not being of childbearing potential is defined as:
    • Age > 55 years with no menses for 12 or more months without an alternative medical cause, or

    • Age ≤ 55 years with no menses for 12 or more months without an alternative medical cause AND an Follicle Stimulating Hormone (FSH) level > 40 IU/L, or

    • Permanent surgical sterility (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).

    1. Female subjects of childbearing potential must have negative results for pregnancy test performed:
    • At Screening with a serum sample obtained within 14 days prior to the first study drug administration, and

    • Prior to dosing with urine sample obtained on Cycle 1 Day 1, if it has been > 7 days since obtaining the serum pregnancy test results.

    Female subjects who are not of childbearing potential at Screening do not require pregnancy testing.

    1. Male subjects sexually active with female partner(s) of childbearing potential, must agree from first dose of study drug(s) through at least 30 days after the last dose of venetoclax or 3 months after the last dose of azacitidine, whichever is later, to practice the protocol specified contraception.

    2. Patient is available for periodic blood sampling, study related assessments, and appropriate clinical management at the treating institution for the duration of the study.

    3. Patient has the ability to understand and willingness to sign an informed consent form indicating the investigational nature of the study.

    4. Patient is able to swallow capsules.

    Exclusion Criteria:
    1. Patient has active and uncontrolled infection.

    2. Patient has active acute or chronic Graft-versus-Host-Disease (GVHD).

    3. Patient receives more than 1mg/kg/day prednisolone.

    4. Patient has uncontrolled intercurrent illness or circumstances that could limit compliance with the study, including but not limited to the following: symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, pancreatitis, or psychiatric or social conditions that may interfere with patient compliance.

    5. Patient is currently participating or has participated in a study with an investigational compound or device within 30 days of initial dosing with study drug.

    6. Patient has known human immunodeficiency virus (HIV) infection or HIV-related malignancy.

    7. Patient has clinically active hepatitis B or hepatitis C infection.

    8. Patient has a known allergy or hypersensitivity to any component of venetoclax or azacitidine.

    9. Patient with a "currently active" second malignancy, other than non-melanoma skin cancer and carcinoma in situ of the cervix, should not be enrolled. Patients are not considered to have a "currently active" malignancy if they have completed therapy for a prior malignancy, are disease free from prior malignancies for > 5 years or are considered by their physician to be at less than 30% risk of relapse.

    10. Patient has received growth factors such as erythropoietin alfa (EPO) or granulocyte colony-stimulating factor (G-CSF) or has received non cytotoxic agents (including low dose oral chemotherapy) in the 30 days before inclusion. In case of previous cytotoxic treatment, an interval of 3 months is required.

    11. Patient is on any systemic steroids that have not been stabilized to the equivalent of ≤ 10 mg/day prednisone during the 4 weeks prior to the start of the study drugs.

    12. Patients with clinical evidence of Central Nervous System leukemia.

    13. Patient has a history of Gastrointestinal surgery or other procedures that might interfere with the absorption or swallowing of the study drugs.

    14. Subject enrolled in a Dose-Escalation cohort has received strong or moderate CYP3A (Cytochrome P450, family 3, subfamily A) inhibitors within 3 days prior to the first dose of study drug.

    15. Patient is unable to take and/or tolerate oral medications on a continuous basis.

    16. Patient is pregnant or breastfeeding within the projected duration of the study.

    17. Subject has a malabsorption syndrome or other condition that precludes an enteral route of administration.

    18. Absence of social security.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 CHU d'Amiens Picardie - Site sud Amiens France 80054
    2 CHU d'Angers Angers France 49933
    3 CHU de Grenoble Grenoble France 38043
    4 Hôpital Dupuytren Limoges France 87042
    5 Hôpital Saint-Eloi Montpellier France 34295
    6 CHU Hôtel Dieu Nantes France 44093
    7 Hôpital l'Archet I Nice France 06200
    8 Hôpital Saint louis Paris France 75010
    9 CHU de Haut-Lévèque Pessac France 33604
    10 Centre Hospitalier Lyon-Sud Pierre-Bénite France 69495
    11 Centre Henri Becquerel Rouen France 76038
    12 Institut de Cancérologie de la Loire Lucien Neuwirth Saint-Priest-en-Jarez France 42270
    13 IUCT Oncopole Toulouse France 31059
    14 Hôpital Brabois Vandœuvre-lès-Nancy France 54500

    Sponsors and Collaborators

    • Groupe Francophone des Myelodysplasies
    • AbbVie

    Investigators

    • Principal Investigator: Thomas CLUZEAU, PHD, CHU de Nice - Hôpital l'Archet I

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Groupe Francophone des Myelodysplasies
    ClinicalTrials.gov Identifier:
    NCT05226455
    Other Study ID Numbers:
    • VENTOGRAFT
    • 2021-000632-56
    First Posted:
    Feb 7, 2022
    Last Update Posted:
    Jul 25, 2022
    Last Verified:
    Jul 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Groupe Francophone des Myelodysplasies
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 25, 2022